Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Single-Dose Pirfenidone in CKD G2-G3a
NCT04126538Phase 1Unknown
- Sponsor
- Gyre Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pirfenidone in chronic kidney disease (CKD) (2 arms), sponsored by Gyre Pharmaceuticals. Primary endpoints: Plasma drug concentrations of pirfenidone up to 24 weeks and Urine concentration of pirfenidone up to 24 weeks. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04126538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126538.